Literature DB >> 15380695

Malignant tumours of the minor salivary glands--a 20 year review.

M J Strick1, C Kelly, J V Soames, N R McLean.   

Abstract

The UK incidence of malignant disease of the minor salivary glands is only 0.6 per million per year. The tumours have a varied histology, can present in any age group and are frequently advanced if located in the sinonasal cavities. In a 20-year review of 21 patients treated for minor salivary gland malignancy in a single institution, it was found that mucoepidermoid tumours were more common in the oral cavity and adenoid cystic carcinomas in the sinonasal tract (p = 0.002). Outcome was variable with sinonasal and adenoid cystic carcinoma having a poorer outcome. Kaplan-Meier curves showed that oral tumours had a higher probability of long term survival. Radical surgery with reconstruction and post-operative adjuvant radiotherapy was effective in achieving loco-regional control. There were no local recurrences within 5 years and three after 5 years. Five patients developed metastatic disease within 10 years and a further two after 10 years. Late recurrences occurred and survival was mainly determined by the presence of systemic disease.

Entities:  

Mesh:

Year:  2004        PMID: 15380695     DOI: 10.1016/j.bjps.2004.04.017

Source DB:  PubMed          Journal:  Br J Plast Surg        ISSN: 0007-1226


  11 in total

1.  Clear cell carcinoma of the base of the tongue: MR imaging findings.

Authors:  N O Uzochukwu; D A Shrier; R J Lapoint
Journal:  AJNR Am J Neuroradiol       Date:  2007-01       Impact factor: 3.825

2.  A retrospective review of malignant minor salivary gland tumors and a proposed protocol for future care.

Authors:  Nickolaos Papadogeorgakis; Eleni Parara; Vasilis Petsinis; Eleni Pappa; Anastasios Nikolaidis; Konstantinos Alexandridis
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2011-03

3.  Malignant minor salivary gland tumors: a retrospective study of 27 cases.

Authors:  Astrid L D Kruse; Klaus W Grätz; Joachim A Obwegeser; Heinz-Theo Lübbers
Journal:  Oral Maxillofac Surg       Date:  2010-12

4.  Adenocarcinoma of the sublingual salivary gland - A case report.

Authors:  Sahana Adirajaiah; Venkatesh Anehosur; K Gopalakrishnan
Journal:  J Oral Biol Craniofac Res       Date:  2012-10-17

5.  Sinonasal tract and nasopharyngeal adenoid cystic carcinoma: a clinicopathologic and immunophenotypic study of 86 cases.

Authors:  Lester D R Thompson; Carla Penner; Ngoc J Ho; Robert D Foss; Markku Miettinen; Jacqueline A Wieneke; Christopher A Moskaluk; Edward B Stelow
Journal:  Head Neck Pathol       Date:  2013-09-15

6.  Minor salivary gland tumours of upper aerodigestive tract: a clinicopathological study.

Authors:  Grażyna Wyszyńska-Pawelec; Michał Gontarz; Jan Zapała; Mariusz Szuta
Journal:  Gastroenterol Res Pract       Date:  2012-05-21       Impact factor: 2.260

Review 7.  Polymorphous low-grade adenocarcinoma: an analysis of epidemiological studies and hints for pathologists.

Authors:  Vera Cavalcanti de Araujo; Fabricio Passador-Santos; Cecilia Turssi; Andresa Borges Soares; Ney Soares de Araujo
Journal:  Diagn Pathol       Date:  2013-01-15       Impact factor: 2.644

8.  Long term control of a maxillary sinus mucoepidermoid carcinoma with low dose radiation therapy: a case report.

Authors:  Horia Vulpe; Meredith Giuliani; David Goldstein; Bayardo Perez-Ordonez; Laura A Dawson; Andrew Hope
Journal:  Radiat Oncol       Date:  2013-10-29       Impact factor: 3.481

9.  Prognostic value of primary tumor surgery in minor salivary-gland carcinoma patients with distant metastases at diagnosis: first evidence from a SEER-based study.

Authors:  Xiao Shi; Nai-Si Huang; Rong-Liang Shi; Wen-Jun Wei; Yu-Long Wang; Qing-Hai Ji
Journal:  Cancer Manag Res       Date:  2018-07-20       Impact factor: 3.989

10.  ELMO3 - a Negative Prognostic Marker in Minor Salivary Gland Carcinoma.

Authors:  Ulana Kotowski; Lorenz Kadletz; Sven Schneider; Felicitas Oberndorfer; Boban M Erovic; Matthaeus Ch Grasl; Claudia Lill; Gregor Heiduschka
Journal:  Pathol Oncol Res       Date:  2018-10-29       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.